Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology
Preprint
- 8 July 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.Keywords
All Related Versions
This publication has 62 references indexed in Scilit:
- CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumorsCancer Immunology, Immunotherapy, 2024
- Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaCancer Cell, 2023
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceCancer Cell, 2022
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyCancer Cell, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2017
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015